问题 › 销售增长停滞 › HealthTech & Digital Health
数字健康公司的收入停滞总是四种情况之一，而本季度通常只有其中一种可行。 对数字健康公司而言，问题出现在特定位置。承载答案的数字是风险收入份额和参与率，而本行业特有的复杂之处在于，成果风险的签署速度快于公司确认自身能否承担该风险的速度——12个月的测量窗口对上11个月的销售周期。这个问题的通用版本与你实际所处的版本，前期动作不同。
数字健康公司的收入停滞总是四种情况之一，而本季度通常只有其中一种可行。 对数字健康公司而言，问题出现在特定位置。承载答案的数字是风险收入份额和参与率，而本行业特有的复杂之处在于，成果风险的签署速度快于公司确认自身能否承担该风险的速度——12个月的测量窗口对上11个月的销售周期。这个问题的通用版本与你实际所处的版本，前期动作不同。
收入只通过四种方式变动：更多注册成员、更高的风险份额或PMPM、更低的客户流失，或能带来归因成果的新产品。所有人都知道这个清单。几乎没人做的是找出当前哪一种未被阻塞，因为一旦签署成果风险，三种通常都已阻塞。
停滞是诊断信息。如果注册成员稳定而收入持平，说明风险份额或参与率未转化。如果新客户下降而收入维持，说明基础流失速度快于补充。如果两者均平且客户流失低，说明对现有合同有响应的细分市场已饱和，下一步是改变风险模型，而非重复原有动作。
停滞持续的原因通常是“卖得更狠”——针对已停止响应现有测量窗口和风险条款的杠杆增加更多活动。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 风险收入份额已签署，但归因成果连续多个季度持平，销售周期却在重复。
✓ 参与率和PMPM无变化，即便注册成员稳定、管道持续刷新。
✓ 客户流失稳定，但风险合同的毛利率未改善，尽管已多次尝试增加活动。
通常会让情况更糟的做法。 在成果尚无法在销售周期内确认的情况下，为风险合同组合增加销售产能，这会将增长问题转化为利润率和现金问题。
It is for you if you run or finance a digital health company and revenue is within a few percent of last year while headcount and cost have grown. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Reduce downside exposure from $7.1M outcomes shortfall to $4.2M while maintaining upside participation in 34 health-plan contracts.
The leak it closes. $2.9M gross profit protected annually through downside cap (difference between $7.1M shortfall at 38% vs $4.2M shortfall at 25%)
The assumption it rests on. Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate — the engine put the probability at 0.7.
| Investment required | $0 incremental — policy change executed by existing legal, finance, and account management teams within current $14M annual burn |
| Expected return | 5.2× on zero incremental investment — derived from $4.2M FY2026 bookings protected relative to status-quo downside exposure |
| Revenue, year 1 | $57.8M ARR (25% at-risk share = $15.5M at-risk revenue vs $23.6M status quo) |
| Revenue, year 2 | $61.4M ARR (assuming 80% contract renewal at 25% cap) |
| Revenue, year 3 | $68.2M ARR (assuming 85% renewal and 10% PMPM stabilization) |
| Exit criteria | Abandon this move if >3 of 8 Q4 2026 contract renewals demand >15% PMPM reduction to accept 25% cap, OR if outcome-prediction accuracy falls below 70% on 10k cohort by Month 9; pivot to fixed-fee PMPM model with optional 15% upside sharing only |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Strategy, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
初期通常两者都不是，而是细分市场问题。你学会销售的细分市场已耗尽，下一个细分市场购买理由不同。针对旧市场的营销和产品调整只会让停滞成本更高，而非缩短停滞时间。
连续两个季度，扣除季节性因素。一个季度持平在多数业务中属于噪音。两个季度则是模式，等待第三个季度的代价是把一年跑道花在已失效的杠杆上。
仅削减已停止响应的杠杆所附带的成本。 uniform 削减会移除仍开放杠杆所需的产能，这通常是停滞转为下滑的方式。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית